320
Participants
Start Date
December 18, 2014
Primary Completion Date
February 29, 2020
Study Completion Date
February 29, 2020
Topiramate
Max therapeutic dose of 200mg/day
Medical Management
Medical Management (MM; Pettinati, 2004) will support subjects' efforts to reduce or stop their drinking. The study nurse makes direct recommendations for reducing drinking to sensible levels. The first session will use the brochure A Guide to Sensible Drinking (WHO 1996). The subject is provided with information about pharmacotherapy and the importance of adherence to topiramate/placebo. Subsequent treatment sessions (15-25 minutes) will be conducted at each study visit, during which the nurse will perform an assessment of the subject's drinking, monitor his/her medication adherence, and make recommendations to follow until the next visit. Men will be advised to consume no more than 3 drinks 4 times per week; women will be advised to consume no more than 2 drinks 4 times per week.
Inactive Placebo
In capsules indistinguishable from topiramate capsules and gradually increased to a maximum equivalent of 200 mg of topiramate/day
Corporal Michael J. Crescenz VA Medical Center, Philadelphia
University of Pennsylvania Treatment Research Center, Philadelphia
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
National Institutes of Health (NIH)
NIH
Department of Health and Human Services
FED
Corporal Michael J. Crescenz VA Medical Center
FED
University of Pennsylvania
OTHER